Fosamax and Osteonecrosis of the Jaw: Examining the Causal Link

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, discussions of medication side effects have historically focused on common, well-documented risks, often framed in terms of patient education and clinical guidance. This heritage provides a baseline for evaluating how pharmaceutical interventions interact with physiological systems over time. As the focus narrows from general health principles to specific exposure scenarios, a critical pivot emerges: the transition from population-level risk communication to individualized exposure assessment. In the domain of mass production, where repetitive manufacturing processes and material handling are routine, the potential for occupational exposure to pharmaceutical compounds or their precursors introduces distinct considerations. This shift requires moving beyond general health advisories toward evaluating how sustained, workplace-related contact with agents such as bisphosphonates may alter risk profiles. The bridge concept here is the recognition that exposure context—whether clinical, environmental, or occupational—fundamentally shapes the relevance and interpretation of health risks. Thus, from the legacy of general health information, we now turn to the specific question of how occupational exposure to Fosamax may relate to the development of osteonecrosis of the jaw, without presupposing mechanistic pathways or citing specific evidence.

Fosamax: Pharmacology and Approved Uses

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation and diagnosis of ONJ typically involves exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is primarily clinical, supported by imaging and histopathology when necessary. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanisms and Risk Factors for ONJ

Fosamax pharmacology involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism is central to its therapeutic effects but also contributes to adverse effects. Reported adverse reactions in clinical trials include gastrointestinal symptoms, musculoskeletal pain, and rare cases of ONJ. In placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The safety profile of once-weekly dosing was similar to daily dosing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistic pathways linking Fosamax to ONJ involve suppression of bone remodeling, which impairs the jawbone's ability to repair microdamage and respond to local infections or trauma. Bisphosphonates accumulate in bone, particularly in areas of high turnover like the jaw, leading to prolonged inhibition of osteoclast activity. This can result in avascular necrosis when combined with local factors such as dental procedures or infection. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Warnings and Causation Considerations

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4, stating that ONJ has been reported in patients taking bisphosphonates, including FOSAMAX (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that ONJ can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use, noting that the optimal duration has not been determined and that for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients require careful evaluation of individual risk factors and temporal relationships. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in susceptible individuals. The timeline between exposure and documented harm can vary widely, from days to months, and may be influenced by concurrent dental procedures or other risk factors. In summary, Fosamax is associated with ONJ, with evidence from clinical reports and mechanistic studies supporting a causal link in some patients. The prescribing information includes warnings about this risk, but individual patient factors and duration of exposure play significant roles in determining risk. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis treatment against the potential for ONJ, particularly in those with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Fosamax cause osteonecrosis of the jaw?

Yes, Fosamax (alendronate) has been associated with osteonecrosis of the jaw (ONJ). Clinical reports and mechanistic studies support a causal link in some patients, particularly those with additional risk factors such as invasive dental procedures, cancer, or prolonged bisphosphonate use. The prescribing information includes a warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is osteonecrosis of the jaw diagnosed?

ONJ is primarily diagnosed clinically based on the presence of exposed bone in the jaw that persists for more than eight weeks, often with pain, swelling, infection, or delayed healing after dental procedures. Imaging and histopathology may support the diagnosis when necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.